10
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          COVID-19 is a disease with heterogeneous clinical appearances. Most patients are asymptomatic or exhibit mild to moderate symptoms; approximately 15% progress to severe pneumonia and about 5% are eventually admitted to the intensive care unit (ICU) due to acute respiratory distress syndrome (ARDS), septic shock and/or multiple organ failure. ICU patients respond poorly to currently available treatments and exhibit a high mortality rate. 1–3 Inadequate identification of the determinants of fatal outcomes is one of the major obstacles to the improvement of the outcomes in severe COVID-19 patients. A previous study reported a scoring system (COVID-GRAM) which accurately predicted the occurrence of critical illness in hospitalized COVID-19 patients. 4 Damage-associated molecular patterns (DAMPs), or alarmins, are a number of molecules, released by stressed cells undergoing microbial infection or sterile injury, that act as danger signals to promote and exacerbate the inflammatory response. 5,6 Of note, the serum level of S100A8/A9 and HMGB1 was found to be correlated with both the severity of pathogen-associated tissue damage and excessive cytokine storm. 7 Despite the hypothesis that S100A8/A9 and HMGB1 are significantly involved in COVID-19, so far, no study has yet tried to substantiate the hypothesis. In this study, we aimed to define the role of S100A8/A9 and HMGB1 in progression to a fatal outcome and develop clinically relevant risk strata for COVID-19 patients. A total of 121 patients were enrolled in this retrospective study, of which 40 patients were in ICU and 81 patients in general wards at enrollment (Table S1). ICU Patients had much higher COVID-GRAM risk scores in comparison to those in general wards. Complications, including ARDS, sepsis, septic shock, secondary infection, acute renal injury, acute cardiac injury or failure, were more frequent in CCOVID-19 patients admitted to ICU. As of the cutoff date of April 30, 2020, most of non-ICU patients (96.3%) had been discharged alive, while 82.5% of ICU patients had died in ICU. COVID-19 patients treated in general wards had significantly elevated level of S100A8/A9 (P = 0.033) but not HMGB1 (P > 0.9999) as compared to healthy controls, suggesting that S100A8/A9 is a more sensitive alarmin than HMGB1 in response to SARS-CoV-2 infection. However, both S100A8/A9 and HMGB1 were significantly elevated extracellularly in ICU-admission patients compared to non-ICU patients, or in fatal outcomes patients compared to alive patients (Fig. 1a–d), indicating that significant elevation of S100A8/A9 and HMGB1 was associated with high mortality. Fig. 1 Serum levels of S100A8/A9 and HMGB1 were strongly correlated with the severity of clinical manifestations and with great predictive power for the risk for ICU admission and death. a, b Comparison of S100A8/A9 and HMGB1 levels between healthy people, non-ICU patients, and ICU patients of COVID-19. c, d Comparison of S100A8/A9 and HMGB1 levels between healthy people, alive patients and dead patients of COVID-19. Spearman’s correlation analyses between S100A8/A9 or HMGB1 levels and peak CT score (e, f), D-dimer level (g, h), neutrophil/lymphocyte ratio (i, j), and quick Sequential Organ Failure Assessment (qSOFA) scores (k, l). m, n Spearman’s correlation analyses of S100A8/A9 or HMGB1 and COVID-GRAM risk score. o, p Comparison of S100A8/A9 or HMGB1 between healthy people and COVID-19 patients of different risk groups (divided according to COVID-GRAM risk score). q, r Receiver operating characteristic (ROC) curve evaluation of the performance of S100A8/A9, HMGB1, combined S100A8/A9 and HMGB1, and COVID-GRAM risk score in distinguish COVID-19 patients with ICU admission or subsequent death. Sixty days survival is shown for patients with different circulating S100A8/A9 levels (s) and different COVID-GRAM risks (t) by Kaplan–Meier curves We further examined the Spearman’s correlation between the serum S100A8/A9 or HMGB1 levels and clinical manifestations in COVID-19 patients. First of all, either serum levels of S100A8/A9 or HMGB1 at admission were positively correlated with peak CT score and oxygen demand, which is indicative of the severity of acute lung injury and ARDS (Fig. 1e, f and S1a, b). Moreover, the degree of organic impairment, as evaluated by the MCP classification, NT-proBNP level, cTn I level, and AKI stage were well correlated with the serum levels of S100A8/A9 or HMGB1 (Fig. S1c–j). The level of peak D-dimer significantly was elevated as the serum S100A8/A9 or HMGB1 increased (Fig. 1g, h). On the other hand, the ratio of neutrophils to lymphocytes was positively correlated with the serum S100A8/A9 but not with HMGB1, suggesting S100A8/A9 plays a more important role in the substantial reduction of the peripheral lymphocytes. The serum S100A8/A9 was strongly correlated with the qSOFA score, 8 a quick indicator of sepsis-related organ dysfunction, indicating that patients with higher S100A8/A9 or HMGB1 levels tended to suffer from more severe sepsis-related organ dysfunction (both P < 0.0001) (Fig. 1i–l). We then evaluated the potential correlation between levels of S100A8/A9 or HMGB1 and COVID-GRAM risk scores. Either levels of S100A8/A9 (P < 0.0001) or HMGB1 (P = 0.030) significantly correlated with the COVID-GRAM risk scores (Fig. 1m, n). Serum levels of S100A8/A9 but not HMGB1 were significantly increased in patient with high risk of COVID-GRAM risk scores which were defined according to the online calculator (http://118.126.104.170) 4 (Fig. 1o, p), highlighting that S100A8/A9 is a better prognostic indicator than HMGB1. The prognostic values of S100A8/A9, HMGB1 or COVID-GRAM risk scores were further evaluated by ROC analysis and their areas under curve were calculated (Fig. 1q, r). For the prediction of ICU admission, the AUCs for COVID-GRAM risk scores with S100A8/A9, HMGB1 and S100A8/A9 and HMGB1 in combination were 0.810, 0.860, 0.781 and 0.901, respectively (Table S2). For the prediction of subsequent death, the AUCs for COVID-GRAM risk scores, S100A8/A9, HMGB1 and S100A8/A9 and HMGB1 in combination were 0.818, 0.875, 0.694 and 0.881, respectively (Table S2). The sensitivity and specificity of S100A8/A9 and HMGB1 of the ROC curves illustrated in Fig. 1q, r were listed in Table S2. The combination of S100A8/A9 with HMGB1 increased the prediction power compared to S100A8/A9 or HMGB1 alone although no significant differences were observed statistically (Table S2). Moreover, higher S100A8/A9 level (P < 0.0001) or higher COVID-GRAM risk score (P < 0.0001) resulted in significant worse overall survival (Fig. 1s, t). The COVID-19 patients were classified into low or high level groups according to the concentrations of S100A8/A9 at a cutoff of 6195 ng/ml, which was set by maximizing Youden’s index according to the ROC curves (Fig. 1s). Meanwhile, the COVID-19 patients were also classified into high-risk or non-high-risk groups according to COVID-GRAM risk scores (Fig. 1t). The hazard ratio of high S100A8/A9 level was 13.32, which was greater than that of COVID-GRAM risk score (HR = 4.612). The concentrations of S100A8/A9 measured at hospital admission showed better predictive power than COVID-GRAM risk scores for subsequent death in COVID-19 patients. To explore the possible correlation between S100A8/A9 or HMGB1 and cytokine storm in COVID-19, the serum levels of S100A8/A9 or HMGB1 were analyzed by Spearman’s correlation tests to know their correlation with of each of the 48 cytokine concentrations in individual patients (Table S3). While the serum levels of S100A8/A9 or HMGB1 correlated with the concentrations of a different spectrum of pro-inflammatory cytokines, 12 cytokines, including IL-8, MCP-3, MCP-1, IL-1ra, β-NGF, IL-7, IL-10, RANTES, G-CSF, IL-1α, CTACK and IL-17A, simultaneously correlated with both the S100A8/A9 and HMGB1. Interestingly, 3 myeloid chemokines, IL-8, MCP-3 and MCP-1, were among the most significant cytokines simultaneously correlated with both the S100A8/A9 and HMGB1 and showed the lowest P value (P < 0.0001), indicating that the overproduced S100A8/A9 and HMGB1 in serum were associated with distinct signatures for cytokine storm in patients with COVID-19. 9,10 In conclusion, this study identified two alarmins, especially S100A8/A9, could accurately identify patients who were subsequently admitted to ICU wards or died with a predictive precision similar to or better than COVID-GRAM risk score. Taking S100A8/A9 as a predictor for COVID-19 might offer some advantages over other clinical or laboratory indicators, since it is easy to measure and the result is easy to interpret. As a single parameter alone, to our knowledge, S100A8/S100A9 is the only one helpful for an early identification of COVID-19 patients who may be admitted to ICU admission or facing death. Using S100A8/A9 to distinguish COVID-19 patients with fatal outcomes is of great clinical significance. Supplementary information Supplemental Material

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study

          Rationale: The global death toll from coronavirus disease (COVID-19) virus as of May 12, 2020, exceeds 286,000. The risk factors for death were attributed to advanced age and comorbidities but have not been accurately defined. Objectives: To report the clinical features of 85 fatal cases of COVID-19 in two hospitals in Wuhan. Methods: Medical records were collected of 85 fatal cases of COVID-19 between January 9, 2020, and February 15, 2020. Information recorded included medical history, exposure history, comorbidities, symptoms, signs, laboratory findings, computed tomographic scans, and clinical management. Measurements and Main Results: The median age of the patients was 65.8 years, and 72.9% were male. Common symptoms were fever (78 [91.8%]), shortness of breath (50 [58.8%]), fatigue (50 [58.8%]), and dyspnea (60 [70.6%]). Hypertension, diabetes, and coronary heart disease were the most common comorbidities. Notably, 81.2% of patients had very low eosinophil counts on admission. Complications included respiratory failure (80 [94.1%]), shock (69 [81.2%]), acute respiratory distress syndrome (63 [74.1%]), and arrhythmia (51 [60%]), among others. Most patients received antibiotic (77 [90.6%]), antiviral (78 [91.8%]), and glucocorticoid (65 [76.5%]) treatments. A total of 38 (44.7%) and 33 (38.8%) patients received intravenous immunoglobulin and IFN-α2b, respectively. Conclusions: In this depictive study of 85 fatal cases of COVID-19, most cases were males aged over 50 years with noncommunicable chronic diseases. The majority of the patients died of multiple organ failure. Early onset of shortness of breath may be used as an observational symptom for COVID-19 exacerbations. Eosinophilopenia may indicate a poor prognosis. A combination of antimicrobial drugs did not offer considerable benefit to the outcome of this group of patients.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Alarmins: awaiting a clinical response.

              Alarmins are endogenous molecules that are constitutively available and released upon tissue damage and activate the immune system. Current evidence indicates that uncontrolled and excessive release of alarmins contributes to the dysregulated processes seen in many inflammatory and autoimmune conditions, as well as tumorigenesis and cancer spread. Conversely, alarmins have also been found to play a major role in the orchestration of tissue homeostasis, including repair and remodeling in the heart, skin, and nervous system. Here, we provide an update and overview on alarmins, highlighting the areas that may benefit from this clinical translation.
                Bookmark

                Author and article information

                Contributors
                Gang.Huang@cchmc.org
                wwang@vip.126.com
                jfzhou@tjh.tjmu.edu.cn
                Journal
                Cell Mol Immunol
                Cell. Mol. Immunol
                Cellular and Molecular Immunology
                Nature Publishing Group UK (London )
                1672-7681
                2042-0226
                3 July 2020
                : 1-3
                Affiliations
                [1 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Department of Hematology, Tongji Hospital, Tongji Medical College, , Huazhong University of Science and Technology, ; No. 1095 Jiefang Avenue, Wuhan, Hubei 430030 China
                [2 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Department of Pediatrics, Tongji Hospital, Tongji Medical College, , Huazhong University of Science and Technology, ; No. 1095 Jiefang Avenue, Wuhan, Hubei 430030 China
                [3 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Department of Medical Imageology, Tongji Hospital, Tongji Medical College, , Huazhong University of Science and Technology, ; No. 1095 Jiefang Avenue, Wuhan, Hubei 430030 China
                [4 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, , Huazhong University of Science and Technology, ; No. 1095 Jiefang Avenue, Wuhan, 430030 China
                [5 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key Cite of National Clinical Research Center for Respiratory Disease, Tongji Hospital, , Tongji Medical College Huazhong University of Science and Technology, ; No. 1095 Jie Fang Avenue, Wuhan, 430030 China
                [6 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, , Huazhong University of Science and Technology, ; Wuhan, 430030 China
                [7 ]ISNI 0000 0000 9025 8099, GRID grid.239573.9, Divisions of Pathology and Experimental Hematology and Cancer Biology, , Cincinnati Children’s Hospital Medical Center, ; 3333 Burnet Avenue, Room S7.224, Cincinnati, OH USA
                [8 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Department of Neurology, Tongji Hospital, Tongji Medical College, , Huazhong University of Science and Technology, ; No. 1095 Jiefang Avenue, Wuhan, 430030 Hubei China
                Article
                492
                10.1038/s41423-020-0492-x
                7332851
                32620787
                71ab1501-ce2f-46e5-99ef-0ddce5e0788b
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 14 June 2020
                : 18 June 2020
                Funding
                Funded by: Emergency Research Project of Tongji Hospital, Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology (2020kfyXGYJ045)
                Funded by: Emergency Research Project of Hubei province (2020FCA006)
                Categories
                Correspondence

                Immunology
                immunology,biomarkers
                Immunology
                immunology, biomarkers

                Comments

                Comment on this article